Latest Medicare News

Page 2 of 16
Rhythm Biosciences has widened access to its ColoSTAT blood test, lifted quarterly revenue 64% and advanced reimbursement and NHS evaluation work. The progress sits alongside A$1.803 million in cash and an estimated 1.22 quarters of funding at the current operating burn.
Ada Torres
Ada Torres
27 Oct 2026
Pacific Edge has secured new US payer access and a Veterans Administration purchasing agreement while proposed Medicare price increases could materially lift revenue per test. The recovery remains unfinished, however, with US commercial volumes down 13% and final Medicare coverage still pending.
Ada Torres
Ada Torres
19 Oct 2026
EBR Systems reported 40 WiSE commercial implants in Q3, down from 46 in Q2 and below its prior forecast, as leadership changes and a sales strategy reset disrupted activity. Higher Medicare reimbursement and progress at its new manufacturing facility offer potential offsets, but both remain dependent on execution and regulatory approval.
Victor Sage
Victor Sage
12 Oct 2026
An independent, Rhythm-funded economic model estimates its ColoSTAT blood test could avoid 29,427 public-hospital colonoscopies a year and deliver $72.4 million in net annual hospital savings. The figures strengthen Rhythm’s planned case for Medicare reimbursement, but remain modelled estimates rather than evidence from real-world use.
Ada Torres
Ada Torres
7 Oct 2026
4DMedical delivered sharp growth in scans, sites and operating revenue as CT:VQ moved into commercial deployment across several global markets. But the company remains loss-making and its auditor issued a qualified opinion over the carrying value of goodwill and other intangible assets.
Victor Sage
Victor Sage
24 Sept 2026
CMS has finalised higher Medicare inpatient reimbursement for EBR Systems’ WiSE System, lifting base payment rates by up to 93% from 1 October 2026. The change improves the commercial payment pathway, although its financial impact will depend on procedure volumes, hospital adoption and NTAP eligibility.
Victor Sage
Victor Sage
21 Sept 2026
PolyNovo delivered 16.1% revenue growth and a sharp improvement in operating cash flow in FY26, despite a lower statutory profit after a prior-year tax benefit and a fire-related write-off. The ASX-listed wound-care company now expects to lodge its U.S. PMA application for NovoSorb BTM before the end of 2026.
Victor Sage
Victor Sage
15 Sept 2026
Pacific Edge is positioning Cxbladder for a Medicare-led recovery, but the company remains loss-making with NZ$7.8 million in net cash after a difficult FY26. The investment case now turns on final US coverage, test volumes and whether the enlarged balance sheet can carry the business to scale.
Ada Torres
Ada Torres
14 Sept 2026
EBR Systems has secured ISO 13485 certification for its new Santa Clara manufacturing site, paving the way for a 500% increase in WiSE System production pending FDA approval expected by year-end.
Ada Torres
Ada Torres
7 Sept 2026
EMVision is progressing its CRC-P funded Regional Benefits Study to evaluate the emu™ bedside brain scanner in remote hospitals, aiming to speed up stroke diagnosis where CT access is limited. Site visits are complete, and protocol development is underway, with relevance extending to similar rural hospitals in the US.
Ada Torres
Ada Torres
3 Sept 2026
4DMedical’s CT:VQ™ lung imaging technology secured FDA clearance and CMS reimbursement, driving rapid adoption in top US medical centres and expanding its addressable market to $3 billion with new clinical programs and European contracts.
Ada Torres
Ada Torres
28 Aug 2026
ImpediMed reported a 15% revenue increase to $14.6 million in FY26, broadened reimbursement coverage for its SOZO platform to 95% of the US population, and launched new applications in heart health and weight management.
Ada Torres
Ada Torres
27 Aug 2026

Browse the archive

Full archive